Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia
Table 1
Patient demographics and diagnosis and details of lipoprotein apheresis treatment.
Patient ()
Age, years
Male () Female ()
Treatment frequency
Processed volume, mL
DALI configuration
Diagnosis
CAD
1
47
Male
Weekly
10000
1250
HyperLp(a)
AWA
2
62
Male
Weekly
10000
1250
HyperLp(a)
Yes
3
52
Male
Biweekly
10000
1250
HyperLp(a)
Yes
4
43
Male
Biweekly
10000
1250
HyperLp(a)
Yes
5
49
Male
Biweekly
10000
1000
HyperLp(a)
Yes
6
52
Female
Biweekly
10000
1250
HyperLp(a)
Yes
7
50
Male
Weekly
10000
1250
HyperLp(a)
Yes
8
73
Male
Biweekly
10000
1000
HyperLp(a)
Yes
9
51
Male
Weekly
10000
1250
HyperLp(a)
Yes
10
63
Male
Weekly
10000
1250
HyperLp(a)
Yes
11
66
Male
Weekly
10000
1250
HyperLp(a)
Yes
DALI, Direct Adsorption of Lipids; HyperLp(a), hyperLp(a)lipoproteinemia; CAD, coronary artery disease; AWA, arterial wall atherosclerosis assessed by angiography but no CAD.
